Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Neuroleptic or Stimulant or [[:Category:REMS medicines|REMS medicine (mandatory ANC monitoring)]]

Use the filters below to narrow your results.

generic:
brand:
None (42) · Benzedrex (1) · Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Phenothiazine D2 antagonist (4) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (59)
starting dose:
None (58) · 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1)
preparations:
None (58) · Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1)
fda max:
None (58) · 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' (1)
routes:
None (58) · Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). (1)
onset:
None (58) · Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)
duration:
None (58) · Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. (1)
halflife:
None (59)
bioavailability:
None (58) · Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' (1)
pregnancy:
None (59)
legal:
None (59)

Showing below up to 59 results in range #1 to #59.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"